Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cadherin EGF LAG Seven-Pass G-Type Receptor 3 (CELSR3) gene overexpression is noted in various cancers.
• CELSR3's role in neurite outgrowth and potential involvement in tumor formation is recognized.
• The clinical significance of CELSR3 in prostate cancer (PCa) remains understudied.

Purpose of the Study:

• To investigate the clinical significance and biological role of CELSR3 in prostate cancer (PCa).
• To analyze CELSR3 expression levels in PCa tissues and cell lines.
• To explore the correlation between CELSR3 expression and PCa progression and patient prognosis.

Main Methods:

• Analysis of public datasets and cell lines to detect CELSR3 expression.
• MTT and migration assays to assess cell proliferation and migration.
• Quantitative real-time PCR to measure hub gene expression (CENPE, CENPA, CDC20, NUF2, ESPL1, PLK1) related to CELSR3.

Main Results:

• Significant increase in CELSR3 expression observed in PCa patients and cell lines.
• CELSR3 downregulation suppressed PCa cell proliferation and migration.
• CELSR3 expression correlated with high PSA levels, advanced pathological stage, high Gleason score, and poor survival outcomes.

Conclusions:

• CELSR3 plays a significant role in prostate cancer progression.
• Increased CELSR3 expression is a potential indicator of poor disease-free survival and prognosis in PCa patients.
• CELSR3's function is closely linked to cell cycle-related signaling pathways.